3rd Covalent Drug Discovery and Development Summit

Topics

• Streamlining Hit Generation with High-Throughput & Unbiased Covalent Screens to Define Innovative Warheads for Hard-to-Drug Targets
• Accelerating the Development of Unbiased & Scalable Platforms to Access & De-Risk Novel Chemistry Amenable for Covalency & Propel Discovery Pipelines
• Spearheading the Specific Covalent Targeting of More Abundant Residues Beyond Cysteine to Access Novel Binding Pockets & Expand the Druggable Proteome
• Advancing Chemoproteomic Platforms & Probes to Better Interrogate Novel Biology & Amplify the Druggable Proteome Outside Oncology
• Debunking & Addressing Idiosyncratic Toxicity Amongst Current Covalency Programs to Improve Safety Profiles & Accelerate IND-Filing
• Fueling the Covalency Renaissance to Increase Investment & Partnership to Expand the Paradigm of Treatable Diseases
• Igniting Covalent Modalities Beyond Inhibition to Harness Diverse Mechanisms of Action for First-in-Class Covalent Drugs
• Examining Pre-Clinical & Translational Cases to Inform & De-Risk the Strategy for Progressing Emerging Covalent Compounds Towards a Quicker Approval